MX370639B - Nueva forma policristalina de profármaco tenofovir, y método de preparación y aplicación del mismo. - Google Patents

Nueva forma policristalina de profármaco tenofovir, y método de preparación y aplicación del mismo.

Info

Publication number
MX370639B
MX370639B MX2017000516A MX2017000516A MX370639B MX 370639 B MX370639 B MX 370639B MX 2017000516 A MX2017000516 A MX 2017000516A MX 2017000516 A MX2017000516 A MX 2017000516A MX 370639 B MX370639 B MX 370639B
Authority
MX
Mexico
Prior art keywords
crystalline form
preparation
present
application therefor
henoxyphosphinyl
Prior art date
Application number
MX2017000516A
Other languages
English (en)
Other versions
MX2017000516A (es
Inventor
Chen Ming
TIAN Chengyao
Zhao Mingli
Yu Jun
Yang Baohai
Lu Aifeng
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of MX2017000516A publication Critical patent/MX2017000516A/es
Publication of MX370639B publication Critical patent/MX370639B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una nueva forma cristalina de 9-[(R)-2-[[(S)[[[1-(isopropoxicarbonil)-1-metil]etil]amino]fenoxi fosfinil]metoxil]propil]adeninafuram ato, y un método de preparación y aplicación para los mismos. Específicamente, la presente invención se refiere a una nueva forma cristalina de 9-[(R)-2-[[(S)-[[[1-(isopropoxicarbonil)-1-metil]etil]amino]fenox ifosfinil]metoxil]propil]adeninafuram ato representado por la fórmula (I), caracterizado porque el patrón de XRPD de la forma cristalina incluye al menos 2? ± 0.20° siendo 5.08, 12.44, 13.18, 22.37, 23.37 y 28.56 los picos de difracción. La forma cristalina de la presente invención tiene características tales como alta biodisponibilidad, eficacia significativa, buena estabilidad, alto rendimiento y alta pureza, y contribuye a la selección y diseño de una ruta de administración de fármaco y la determinación de parámetros de proceso de una preparación farmacéutica, mejorando así la calidad de la producción de fármacos.
MX2017000516A 2014-07-21 2015-07-21 Nueva forma policristalina de profármaco tenofovir, y método de preparación y aplicación del mismo. MX370639B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410349141.4A CN105399771B (zh) 2014-07-21 2014-07-21 替诺福韦前药晶型及其制备方法和用途
PCT/CN2015/084671 WO2016011932A1 (zh) 2014-07-21 2015-07-21 替诺福韦前药新多晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
MX2017000516A MX2017000516A (es) 2017-09-01
MX370639B true MX370639B (es) 2019-12-17

Family

ID=55162513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000516A MX370639B (es) 2014-07-21 2015-07-21 Nueva forma policristalina de profármaco tenofovir, y método de preparación y aplicación del mismo.

Country Status (12)

Country Link
US (1) US9840525B2 (es)
EP (1) EP3173417A4 (es)
JP (1) JP6872179B2 (es)
KR (1) KR102476361B1 (es)
CN (2) CN105399771B (es)
AU (1) AU2015292050B2 (es)
BR (1) BR112017000605B1 (es)
CA (1) CA2954395C (es)
MX (1) MX370639B (es)
RU (1) RU2701728C2 (es)
TW (1) TWI718990B (es)
WO (1) WO2016011932A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
AU2004206827A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CN102240295B (zh) * 2005-06-13 2013-04-03 博瑞生物医药技术(苏州)有限公司 泰诺福韦衍生物及用途
CN100396689C (zh) 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
US9187508B2 (en) * 2010-08-01 2015-11-17 Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Crystalline forms of tenofovir dipivoxil fumarate
ES2661705T3 (es) * 2011-10-07 2018-04-03 Gilead Sciences, Inc. Métodos para la preparación de análogos de nucleótidos antivirales
CN103665043B (zh) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
KR101703258B1 (ko) 2014-12-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법

Also Published As

Publication number Publication date
RU2017102321A3 (es) 2018-12-06
TWI718990B (zh) 2021-02-21
CA2954395C (en) 2022-08-16
TW201623323A (zh) 2016-07-01
CN106536532B (zh) 2019-09-03
CN105399771A (zh) 2016-03-16
KR20170033862A (ko) 2017-03-27
CN106536532A (zh) 2017-03-22
WO2016011932A1 (zh) 2016-01-28
EP3173417A1 (en) 2017-05-31
CN105399771B (zh) 2020-11-24
JP2017522301A (ja) 2017-08-10
AU2015292050A1 (en) 2017-02-02
RU2701728C2 (ru) 2019-10-01
MX2017000516A (es) 2017-09-01
AU2015292050B2 (en) 2019-01-31
JP6872179B2 (ja) 2021-05-19
US9840525B2 (en) 2017-12-12
US20170204125A1 (en) 2017-07-20
RU2017102321A (ru) 2018-08-21
KR102476361B1 (ko) 2022-12-09
BR112017000605B1 (pt) 2023-04-18
BR112017000605A2 (pt) 2017-11-07
CA2954395A1 (en) 2016-01-28
EP3173417A4 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
MX2024001890A (es) Preparacion de psilocibina, diferentes formas polimorficas, intermediarios, formulaciones, y su uso.
WO2012122340A8 (en) Soluble guanylate cyclase activators
MD4664C9 (ro) Lactame aril şi heteroaril condensate
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
IN2014CN00989A (es)
MY198066A (en) Method for the preparation of (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
MX2019011844A (es) Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.
MX2019006165A (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
ZA201805240B (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
IN2013MN02170A (es)
WO2013121235A3 (en) Process for preparation of dronedarone by removal of hydroxyl group
MX2013014577A (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX370639B (es) Nueva forma policristalina de profármaco tenofovir, y método de preparación y aplicación del mismo.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
MY191352A (en) Aldosterone synthase inhibitors
WO2012176218A8 (en) Process for preparing rosuvastatin calcium through novel amine salt
MX2018008799A (es) Derivado de azaciclo amida, metodo de preparacion del mismo y aplicacion farmaceutica.
MX2019012257A (es) Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
IN2015DN02616A (es)
NZ740119A (en) Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide

Legal Events

Date Code Title Description
FG Grant or registration